Scarica l'app Stockscreener
1.32
0.75%
-0.01
Precedente Chiudi:
$1.33
Aprire:
$1.32
Volume 24 ore:
4,339
Relative Volume:
0.17
Capitalizzazione di mercato:
$7.25M
Reddito:
$3.25M
Utile/perdita netta:
$-8.34M
Rapporto P/E:
-0.5125
EPS:
-2.5755
Flusso di cassa netto:
$-7.71M
1 W Prestazione:
-2.94%
1M Prestazione:
+3.12%
6M Prestazione:
+88.57%
1 anno Prestazione:
-36.54%
Intervallo 1D:
$1.32
$1.34
Intervallo di 1 settimana:
$1.31
$1.40
Portata 52W:
$0.575
$2.33
Inmed Pharmaceuticals Inc Stock (INM) Company Profile
Nome
Inmed Pharmaceuticals Inc
Settore
Telefono
(604) 669-7207
Indirizzo
1445-885 WEST GEORGIA ST., VANCOUVER
Compare INM vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INM
Inmed Pharmaceuticals Inc
|
1.32 | 7.25M | 3.25M | -8.34M | -7.71M | -2.5755 |
TAK
Takeda Pharmaceutical Co Adr
|
19.67 | 62.84B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.50 | 48.40B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.13 | 44.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.38 | 32.80B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
533.12 | 22.87B | 3.17B | 1.29B | 1.01B | 27.09 |
Inmed Pharmaceuticals Inc Borsa (INM) Ultime notizie
At $1.32–$1.33 a share, ADAR1 funds buy 9,569 shares of InMed Pharmaceuticals (INM). - Stock Titan
Form 4 InMed Pharmaceuticals Inc. For: 12 October By Investing.com - Investing.com South Africa
Form 4 InMed Pharmaceuticals Inc. For: 8 October By Investing.com - Investing.com South Africa
Form 4 InMed Pharmaceuticals Inc. For: 8 October By Investing.com - Investing.com UK
Across October 6–8, ADAR1 funds buy 10,903 shares of InMed Pharmaceuticals (INM). - Stock Titan
Funds hold 943,668 InMed Pharmaceuticals (INM) shares, with voting power shared by two reporting persons. - Stock Titan
Across three transactions, ADAR1 funds buy 42,920 InMed Pharmaceuticals (INM) shares. - Stock Titan
Form 8K INMED PHARMACEUTICALS INC. For: 18 September By Investing.com - Investing.com Nigeria
Nasdaq gives InMed 45 days to submit a compliance plan - Stock Titan
10% owner adds to InMed Pharmaceuticals (INM) stake with open-market buys - Stock Titan
InMed Reports FY2026 Net Loss Of $12.9 Million As Mentari Merger Advances With $490 Million Financing - Pulse 2.0
InMed winds down only revenue-generating business BayMedica - Minichart
[S-4/A] InMed Pharmaceuticals Inc. Amended Business Combination Registration | INM SEC FilingForm S-4/A - Stock Titan
$490M backs proposed migraine merger at InMed Pharmaceuticals (INM)—what legacy holders keep - Stock Titan
InMed Pharmaceuticals Inc. FY 2026: Revenue $3.18M, EPS ($3.12) — 10-K Summary - TradingView
About $490 million in financing is expected before a proposed merger. InMed still needs shareholder approval. - Stock Titan
InMed Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
GOOG: Alphabet IncOrdinary SharesClass C Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
InMed (INM) Earnings Update: The Company Publishes Its Latest Results in the Latest Session; Price Reaction: Shares Close 7.59% Lower for the Current SessionSegment Revenue Breakdown - vinanet.vn
InMed (INM) Price: Finishes 7.59% Down at $1.46 in the Latest Session; Technical Setup: Price Remains Between $1.39 Support and $1.53 Resistance under the Current SnapshotIntraday Profile - vinanet.vn
InMed (INM) Price: Finishes 7.59% Down at $1.46 in the Latest Session; Technical Setup: Price Remains Between $1.39 Support and $1.53 Resistance under the Current SnapshotShort Setup Alerts - siam.in
InMed (INM) Price: Finishes 7.59% Down at $1.46 in the Latest Session; Technical Setup: Price Remains Between $1.39 Support and $1.53 Resistance under the Current SnapshotVol Target Rebalance - dars.gov.et
InMed (INM) Q3 2025 Results: The Latest Report Adds New Financial Reference Points at the Close; Session Move: Shares Move 0.63% Lower in the Current UpdateEarnings Growth Forecast - vinanet.vn
InMed (INM) Session: Adds 0.63% to Close at $1.60 in Latest Trading; Current Setup: Traders Can Monitor the $1.52-$1.68 RangeVolatility Skew - vinanet.vn
InMed (INM) Q3 2025 Results: The Latest Report Adds New Financial Reference Points at the Close; Session Move: Shares Move 0.63% Lower in the Current UpdateAnalyst Earnings Estimate - careplusvn.com
InMed (INM) Session: Adds 0.63% to Close at $1.60 in Latest Trading; Current Setup: Traders Can Monitor the $1.52-$1.68 RangeBollinger Walk - dars.gov.et
InMed (INM) Q3 2025 Results: The Latest Report Adds New Financial Reference Points at the Close; Session Move: Shares Move 0.63% Lower in the Current UpdateNegative Surprise Momentum - dars.gov.et
InMed (INM) Q3 2025 Results: The Latest Report Adds New Financial Reference Points at the Close; Session Move: Shares Move 0.63% Lower in the Current UpdateAnalyst Consensus Shift - dars.gov.et
InMed (INM) Q3 2025 Results: The Latest Report Adds New Financial Reference Points at the Close; Session Move: Shares Move 0.63% Lower in the Current UpdateRevenue Per Share - dars.gov.et
InMed (INM) Q3 2025 Results: The Latest Report Adds New Financial Reference Points at the Close; Session Move: Shares Move 0.63% Lower in the Current UpdateEarnings Surprise Stocks - dars.gov.et
InMed (INM) Q3 2025 Results: The Latest Report Adds New Financial Reference Points at the Close; Session Move: Shares Move 0.63% Lower in the Current UpdateUpward Estimate Revision - dars.gov.et
InMed Pharmaceuticals (INM) Holds Above Support After 2.8% GainCash Secured Put - vinanet.vn
InMed Pharmaceuticals (INM) Holds Above Support After 2.8% GainKey Reversal Day - dars.gov.et
INM Q3 2025 Earnings: Net Loss of $1.94 Per Share; Stock Rises 2.8%One-Time Gain Impact - vinanet.vn
InMed Pharmaceuticals (INM) investor reports 4.2% beneficial stake in 137,634 shares - Stock Titan
Inmed Pharmaceuticals Stock Price Forecast. Should You Buy INM? - StockInvest.us
INM Q3 2025 Earnings: Net Loss of $1.94 Per Share Reflects Ongoing Biopharmaceutical InvestmentRevenue Breakdown Analysis - vinanet.vn
INM Q3 2025 Earnings: Net Loss of $1.94 Per Share ReportedFinancial Data - Vinanet
InMed Pharmaceuticals (INM) Rises 3.55% to $1.46 as Buyers Defend Key SupportMA Crossover - dars.gov.et
InMed Pharmaceuticals (INM) Rises 3.55% to $1.46 as Buyers Defend Key SupportBlue Chip Entry Points - vinanet.vn
InMed Pharmaceuticals Inc (INM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
InMed Pharmaceuticals (INM) Slips 6% to $1.40 as Support Level Comes into FocusDefined Outcome ETF - vinanet.vn
InMed Pharmaceuticals (INM) Rises 2.40% as Shares Approach Key $1.58 ResistanceSector Leader Stocks - vinanet.vn
INM Q3 2025 Earnings: Net Loss of $1.94 Per Share Reflects Ongoing Clinical InvestmentNet Profit Margin - vinanet.vn
INM Q3 2025 Earnings: Narrowing Losses and Cautious Pipeline ProgressRevenue Growth Report - vinanet.vn
InMed Pharmaceuticals Inc (INM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
InMed Pharmaceuticals Inc (INM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
InMed Pharmaceuticals Inc (INM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
InMed Pharmaceuticals Inc (INM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
InMed Pharmaceuticals Inc (INM) Institutional Confidence - TradingKey
Inmed Pharmaceuticals Inc Azioni (INM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Inmed Pharmaceuticals Inc Azioni (INM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 10% Owner |
Oct 15 '26 |
Buy |
1.32 |
984 |
1,301 |
955,493 |
| ADAR1 Capital Management, LLC | 10% Owner |
Oct 13 '26 |
Buy |
1.33 |
564 |
750 |
946,488 |
| ADAR1 Capital Management, LLC | 10% Owner |
Oct 08 '26 |
Buy |
1.33 |
2,256 |
2,997 |
945,924 |
| ADAR1 Capital Management, LLC | 10% Owner |
Oct 07 '26 |
Buy |
1.33 |
3,046 |
4,051 |
943,668 |
| ADAR1 Capital Management, LLC | 10% Owner |
Oct 06 '26 |
Buy |
1.33 |
5,601 |
7,436 |
940,622 |
| ADAR1 Capital Management, LLC | 10% Owner |
Oct 05 '26 |
Buy |
1.33 |
18,182 |
24,182 |
935,021 |
| ADAR1 Capital Management, LLC | 10% Owner |
Oct 02 '26 |
Buy |
1.33 |
8,307 |
11,048 |
916,839 |
| ADAR1 Capital Management, LLC | 10% Owner |
Oct 01 '26 |
Buy |
1.33 |
16,431 |
21,850 |
908,532 |
| ADAR1 Capital Management, LLC | 10% Owner |
Sep 16 '26 |
Buy |
1.29 |
8,340 |
10,750 |
892,101 |
| ADAR1 Capital Management, LLC | 10% Owner |
Sep 15 '26 |
Buy |
1.30 |
54,256 |
70,446 |
883,761 |
7.97%
3.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):